1Children’s Hospital Augsburg, Swabian Children’s Cancer Center, Stenglinstr. 2, 86156 Augsburg, Germany; 2Institute of Neuropathology, University Hospital Münster, Pottkamp 2, 48149 Münster, Germany; 3Department of Human Genetics, Institute of Human Genetics, University of Ulm, Ulm, Germany; 4Department of Pediatric Hematology and Oncology, University Medical Center Hamburg Eppendorf, Martinistraße 52, 20246 Hamburg, Germany; 5Division of Pediatric Neurooncology (B062), German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
The EU-RHAB registry prospectively collects data on uniformly treated patients, to define a standard of care and to lay the foundation for phase I/II trials. 118 patients with AT/RT were evaluable. Reference evaluation of neuropathology, imaging, molecular diagnostics and treatment followed the EU-RHAB guidelines. Genetic analyses of the tumor suppressor gene SMARCB1 (FISH, MLPA, sequencing) and Illumina 450 k methylation profiling segregated molecular subgroups.
54% of tumours were located infratentorially, 1.7% spinal only. Eight patients had synchronous tumours. In 20 of 92 patients a germ-line mutation (GLM) was detected. Metastases were observed in 44, a complete resection (GTR) was achieved in 39 patients. 71% completed EU-RHAB chemotherapy (in 30 high dose chemotherapy was applied). 80 patients received radiotherapy (RT), 18 of them with protons, and 27 patients obtained maintenance therapy. A CR was achieved in 62 patients, in 15 by surgery alone and in 47 by additional chemotherapy. Complete genetic analysis of SMARCB1 was obtained in 68, 450 k methylation profiles in 47 patients. 5-year OS and EFS rates were significantly associated with age at diagnosis, metastasis, GLM, GTR, RT, CR, genetic subgroups of SMARCB1 and 450 k methylation profile. Patients with mutation (frame shift, splice site mutation, intragenic deletion) on both alleles of SMARCB1 had inferior outcomes (57.8% ± [0.11] vs. 12% ± [0.07]). Furthermore the TYR-subgroup defined by 450 k methylation profiling appeared to confer a significant survival benefit (36.3% ± [0.15] vs. 25% ± [0.14]).
According to the presented data and ongoing research we suggest developing a risk-adapted strategic European approach for patients affected by AT/RT.
References
1. Atypical teratoid/rhabdoid tumors-current concepts, advances in biology, and potential future therapies. Frühwald MC, Biegel JA, Bourdeaut F, Roberts CW, Chi SN. Neuro Oncol. 2016;18(6):764–78.
2. Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. Johann PD, Erkek S, Zapatka M, Kerl K, Buchhalter I, Hovestadt V, Jones DT, Sturm D, Hermann C, Segura Wang M, Korshunov A, Rhyzova M, Gröbner S, Brabetz S, Chavez L, Bens S, Gröschel S, Kratochwil F, Wittmann A, Sieber L, Geörg C, Wolf S, Beck K, Oyen F, Capper D, van Sluis P, Volckmann R, Koster J, Versteeg R, von Deimling A, Milde T, Witt O, Kulozik AE, Ebinger M, Shalaby T, Grotzer M, Sumerauer D, Zamecnik J, Mora J, Jabado N, Taylor MD, Huang A, Aronica E, Bertoni A, Radlwimmer B, Pietsch T, Schüller U, Schneppenheim R, Northcott PA, Korbel JO, Siebert R, Frühwald MC, Lichter P, Eils R, Gajjar A, Hasselblatt M, Pfister SM, Kool M. Cancer Cell. 2016 14;29(3):379–93.
3. Improved 6-year overall survival in AT/RT - results of the registry study Rhabdoid 2007. Bartelheim K, Nemes K, Seeringer A, Kerl K, Buechner J, Boos J, Graf N, Dürken M, Gerss J, Hasselblatt M, Kortmann RD, Teichert von Luettichau I, Nagel I, Nygaard R, Oyen F, Quiroga E, Schlegel PG, Schmid I, Schneppenheim R, Siebert R, Solano-Paez P, Timmermann B, Warmuth-Metz M, Frühwald MC. Cancer Med. 2016 Aug;5(8):1765–75.